Unknown PHASE2 INTERVENTIONAL 2-arm NCT04970693

A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

A Phase II Single-arm Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression After First-line EGFR-TKI Therapy

Sponsor: Sun Yat-sen University

Conditions Non-small Cell Lung Cancer Oligoprogressive

Interventions Furmonertinib

Updated 3 times since 2021 Last updated: Jul 10, 2021 Started: Jun 1, 2021 Primary completion: Jan 31, 2024 Completion: May 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04970693, this PHASE2 trial focuses on Non-small Cell Lung Cancer and Oligoprogressive and remains ongoing. Sponsored by Sun Yat-sen University, it has been updated 3 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2021 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China